Hill AM - Search Results

1

Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?

Martin NK, Boerekamps A, Hill AM, Rijnders BJA. Martin NK, et al. Among authors: hill am. J Int AIDS Soc. 2018 Apr;21 Suppl 2(Suppl Suppl 2):e25062. doi: 10.1002/jia2.25062. J Int AIDS Soc. 2018. PMID: 29633560 Free PMC article. Review.

2

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.

van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, Hill A. van de Ven N, et al. Hepatology. 2015 Apr;61(4):1174-82. doi: 10.1002/hep.27641. Epub 2015 Feb 9. Hepatology. 2015. PMID: 25482139 Free PMC article.

3

Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.

Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, Londeix P, Forette C, Momenghalibaf A, Verster A, Swan T. Ford N, et al. Int J Drug Policy. 2015 Nov;26(11):1088-93. doi: 10.1016/j.drugpo.2015.05.004. Epub 2015 May 18. Int J Drug Policy. 2015. PMID: 26074094

4

Viral dynamics in hepatitis B virus infection.

Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Nowak MA, et al. Among authors: hill am. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402. doi: 10.1073/pnas.93.9.4398. Proc Natl Acad Sci U S A. 1996. PMID: 8633078 Free PMC article.

5

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E. Hill AM, et al. Pharmacoeconomics. 2010;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000. Pharmacoeconomics. 2010. PMID: 21182345 Clinical Trial.

6

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Hill A, et al. Clin Infect Dis. 2014 Apr;58(7):928-36. doi: 10.1093/cid/ciu012. Epub 2014 Jan 6. Clin Infect Dis. 2014. PMID: 24399087 Free PMC article.

7

Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of break points.

Raymond A, Hill A, Pozniak A. Raymond A, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19507. doi: 10.7448/IAS.17.4.19507. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394016 Free PMC article.

8

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.

Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A. Antinori A, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19525. doi: 10.7448/IAS.17.4.19525. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394034 Free PMC article.

9

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up.

Lanzafame M, Lattuada E, Rigo F, Hill A, Vento S. Lanzafame M, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19822. doi: 10.7448/IAS.17.4.19822. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397566 Free PMC article.

10

Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.

Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Simmons B, et al. Clin Infect Dis. 2015 Sep 1;61(5):730-40. doi: 10.1093/cid/civ396. Epub 2015 May 17. Clin Infect Dis. 2015. PMID: 25987643 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

370 results

Search Page

Filters